RxDoctor Payments Data

William Ray, MD

Internal Medicine · Bloomington, ILNPI 1689672859

Payments from drug & device makers

$1,205in general payments, 2019–2025

Across 29 payments — averaging $41.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$552
  • Lilly USA, LLC$270
  • Phathom Pharmaceuticals, Inc.$142
  • Aimmune Therapeutics, Inc.$115
  • Abbott$60
  • Radius Health, Inc.$51
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$1,205100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,205 in reported general payments places this provider in the 75th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$94,449
Medicare patients
171
Services billed
7,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban120$77,780
OzempicSemaglutide41$49,411
XareltoRivaroxaban41$32,940
JardianceEmpagliflozin24$31,382
RybelsusSemaglutide18$27,826
MounjaroTirzepatide14$20,656
Tolvaptan13$9,682
JanuviaSitagliptin Phosphate12$8,973
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,806
PaxlovidNirmatrelvir/Ritonavir30$5,760
MyrbetriqMirabegron11$5,379
Rosuvastatin Calcium415$3,998
Metoprolol Succinate256$2,987
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$2,050
Losartan Potassium200$1,936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$552$77,23859 claims
Lilly USA, LLCMounjaro$270$20,65614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Bloomington

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →